As competitive as the obesity drug market has become, Novo Nordisk's decision to slash the prices of its GLP-1 agonist drugs ...

Eli Lilly (NYSE: LLY) has officially joined the trillion-dollar market cap club, cementing its place among the world’s most ...

Orforglipron is Lilly’s oral GLP-1 in phase 3 development as a treatment for diabetes and obesity. The FDA is expected to approve the drug in March 2026. Lilly’s November news release states that the ...

Several of the environmental advocates and vaccine skeptics who helped propel Kennedy into politics have become impatient ...

Donald Trump's family has been pursuing wealth, fame and power in their name for decades, and now that he is a lame-duck ...

In summary, under the Trump plan, the U.S. health system continues to fail Americans — by not viewing obesity as a disease, ...

This week on "The Readout LOUD," STAT reporters have an in-depth chat with Mark Cuban about the direct-to-consumer trend and ...

Drug expenditure far outpaces in the U.S. with $2,000 per capita spending in 2022, leading 11 global markets including Japan and Germany.

Novo Nordisk's discounted valuations and promising oral candidate may trigger a drastic reversal in its stock ...

During a fireside chat with Scripta Insights’ CEO, Cuban discussed TrumpRx and unveiled new MCCPDC innovations, including ...

In a virtual fireside chat on Tuesday with Scripta Insights CEO Eric Levin, Mark Cuban spoke passionately about the potential ...